KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Change in Cash (2016 - 2025)

Historic Change in Cash for BeOne Medicines (ONC) over the last 11 years, with Q3 2025 value amounting to $1.3 billion.

  • BeOne Medicines' Change in Cash rose 128690.85% to $1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 billion, marking a year-over-year increase of 48020.43%. This contributed to the annual value of -$547.2 million for FY2024, which is 2058.13% up from last year.
  • According to the latest figures from Q3 2025, BeOne Medicines' Change in Cash is $1.3 billion, which was up 128690.85% from $255.5 million recorded in Q2 2025.
  • In the past 5 years, BeOne Medicines' Change in Cash registered a high of $3.4 billion during Q4 2021, and its lowest value of -$397.0 million during Q3 2021.
  • Over the past 5 years, BeOne Medicines' median Change in Cash value was -$108.2 million (recorded in 2025), while the average stood at $163.7 million.
  • In the last 5 years, BeOne Medicines' Change in Cash soared by 434428.68% in 2021 and then tumbled by 106492.95% in 2023.
  • Quarter analysis of 5 years shows BeOne Medicines' Change in Cash stood at $3.4 billion in 2021, then plummeted by 109.62% to -$325.5 million in 2022, then surged by 132.29% to $105.1 million in 2023, then plummeted by 171.06% to -$74.7 million in 2024, then surged by 1873.48% to $1.3 billion in 2025.
  • Its Change in Cash was $1.3 billion in Q3 2025, compared to $255.5 million in Q2 2025 and -$108.2 million in Q1 2025.